NASDAQ:CSCI COSCIENS Biopharma (CSCI) Stock Price, News & Analysis $2.71 -0.23 (-7.82%) Closing price 04/3/2025 03:59 PM EasternExtended Trading$2.71 0.00 (0.00%) As of 04/3/2025 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsTrendsBuy This Stock About COSCIENS Biopharma Stock (NASDAQ:CSCI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get COSCIENS Biopharma alerts:Sign Up Key Stats Today's Range$2.70▼$2.8650-Day Range$2.57▼$4.3552-Week Range$1.96▼$6.77Volume5,396 shsAverage Volume14,083 shsMarket Capitalization$10.23 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCOSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.Read More… Remove Ads Receive CSCI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for COSCIENS Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address CSCI Stock News HeadlinesCOSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade OrderApril 1 at 7:32 PM | financialpost.comCOSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade OrderApril 1 at 7:25 PM | globenewswire.comBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical technology that could change society forever and make early investors rich.April 4, 2025 | Stansberry Research (Ad)COSCIENS Biopharma Faces Potential Delay in Year-End Filings Due to Merger ComplexitiesMarch 19, 2025 | tipranks.comCOSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting DocumentsMarch 19, 2025 | financialpost.comCOSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting DocumentsMarch 19, 2025 | gurufocus.comCOSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting DocumentsMarch 19, 2025 | globenewswire.comCOSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory ProductMarch 13, 2025 | financialpost.comSee More Headlines CSCI Stock Analysis - Frequently Asked Questions How have CSCI shares performed this year? COSCIENS Biopharma's stock was trading at $2.77 at the beginning of 2025. Since then, CSCI shares have decreased by 2.2% and is now trading at $2.71. View the best growth stocks for 2025 here. How were COSCIENS Biopharma's earnings last quarter? COSCIENS Biopharma Inc. (NASDAQ:CSCI) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($1.85) earnings per share (EPS) for the quarter. The company earned $1.87 million during the quarter. COSCIENS Biopharma had a negative trailing twelve-month return on equity of 95.93% and a negative net margin of 428.43%. How do I buy shares of COSCIENS Biopharma? Shares of CSCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of COSCIENS Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that COSCIENS Biopharma investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Amgen (AMGN), AstraZeneca (AZN) and Baidu (BIDU). Company Calendar Last Earnings11/12/2024Today4/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CSCI CIK1113423 Webwww.cosciensbio.com Phone49-6942-6020Fax418-948-9191Employees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($11.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,550,000.00 Net Margins-428.43% Pretax Margin-547.63% Return on Equity-95.93% Return on Assets-45.66% Debt Debt-to-Equity RatioN/A Current Ratio3.46 Quick Ratio3.05 Sales & Book Value Annual Sales$7.60 million Price / Sales1.35 Cash FlowN/A Price / Cash FlowN/A Book Value$14.99 per share Price / Book0.18Miscellaneous Outstanding Shares3,776,000Free Float3,772,000Market Cap$10.23 million OptionableN/A Beta1.47 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:CSCI) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding COSCIENS Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share COSCIENS Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.